Roth MKM Maintains Buy on Cyclacel Pharmaceuticals, Raises Price Target to $21
Roth MKM Maintains Buy on Cyclacel Pharmaceuticals, Raises Price Target to $21
羅斯MKM維持對Cyclacel Pharmicals的買入,將目標股價提高至21美元
Roth MKM analyst Jonathan Aschoff maintains Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a Buy and raises the price target from $16 to $21.
羅斯MKM分析師喬納森·阿肖夫維持Cyclacel Pharmicals(納斯達克股票代碼:CYCC)的買入,並將目標股價從16美元上調至21美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。